Merck to Acquire Pandion for ~$1.85B
Shots: Merck to acquire all outstanding share of Pandion for $60/share in cash, representing the equity value of ~$1.85B. The transaction is expected to close in H1’21 The acquisition will strengthen Merck’s portfolio with the addition of candidates targeting a broad range of autoimmune diseases Pandion is advancing a pipeline of precision immune modulators targeting […]